Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference Life Science Investing
Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones Life Science Investing
Aytu BioPharma Details Agenda for Investor Day Scheduled for January 20, 2026 in New York City Life Science Investing
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference Life Science Investing
Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026 Life Science Investing
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue Life Science Investing
Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases Life Science Investing
Doseology Engages McKinney Regulatory Science Advisors to Advance Innovative Oral Pouch Product Development through Science and Regulatory Expertise Life Science Investing
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis with Its Novel Bispecific Antibody ATI-052 Life Science Investing
Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate Life Science Investing
BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026
